Skip to content

Combined Effects of Nutritional and Exercise Countermeasures

Combined Effects of Nutritional and Exercise Countermeasures

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00447044
Enrollment
31
Registered
2007-03-13
Start date
2007-01-31
Completion date
2009-06-30
Last updated
2009-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscular Atrophy, Muscle Weakness

Keywords

Muscle loss and Maintenance of Muscle function

Brief summary

The purpose of this study is to see if a combination of resistance exercises and amino acid capsules can reduce muscle loss and maintain muscle function during bedrest. This experiment will imitate many of the physical conditions experienced by astronauts during space flight by examining the effects of resistance exercise or nutrition on muscle during 2 days of bedrest. The diet of astronauts will also be imitated by providing diets in the General Clinic Research Center.

Interventions

BEHAVIORALResistance Exercise

Subjects will lift weights with their legs.

DIETARY_SUPPLEMENTdiet orange soda

Subjects drink diet orange soda 3x day for 2 days.

DIETARY_SUPPLEMENTessential amino acids

Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-50 years of age * Availability of transport and ability to report to Research Center at appointed times

Exclusion criteria

* Subjects with limiting or unstable angina or a cardiology confirmed ECG which demonstrates cardiac abnormalities such as \> 0.2 mV horizontal or downsloping ST segment depression, frequent arrhythmia's (\>10 PVC/min), or valvular disease. * Subjects with vascular disease as determined by a combination of risk factors of peripheral atherosclerosis, namely hypertension, obesity, diabetes, hypercholesterolemia and/or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal, and pedal arteries. * Any history of hypo- or hyper-coagulation disorders including subjects taking Coumadin or with a history of DVT or PE at any point in their lifetime. * Any subject that has a chronically elevated systolic pressure \>170 or a diastolic blood pressure \> 100 will be excluded. Subjects may be included if they are taking blood pressure medication and have a blood pressure below these criteria. * Any subject with an uncontrolled metabolic disease including liver or renal disease. * Fasting blood glucose of \>126 mg/dl on two separate occasions * Presence of acute illness or metabolically unstable chronic illness. * Any subject currently on weight-loss diet. * Inability to abstain from smoking for duration of study. * Recent ingestion of anabolic steroids (within 6 months). * Subjects with atrial fibrillation, history of syncope, angina or congestive heart failure. * Subjects with a recently (6 months) treated cancer other than Basal Cell Carcinoma. * Pregnancy/lactation. * Any other condition or event considered exclusionary by the PI and covering faculty

Design outcomes

Primary

MeasureTime frame
Fractional synthetic rate of muscle growth.two days.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026